Apple debunks the hype around A.I. with a study showing that models struggle with complex reasoning, despite advanced ...

It is difficult to walk past the newest mural on Darwin’s Spain Place and not stop for a moment to take it in.

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical ...

After layoffs at Recursion, the company’s CEO writes about taking inspiration from an unexpected source: “The Art of Racing ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of ...

Recursion Pharmaceuticals (RXRX) stock gains as the company plans a 20% workforce reduction to streamline operations and ...

Recursion Pharmaceuticals said on Tuesday it will lay off around 20% of its workforce and focus on developing drugs for rare diseases and cancers to reduce cash burn during a prolonged biotech ...

Based on its latest expense profile and business plan, after cutting its staff, Recursion said it now expects its projected cash runway to extend into the fourth quarter of 2027. Recursion will pay ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

This important study demonstrates the significance of incorporating biological constraints in training neural networks to develop models that make accurate predictions under novel conditions. By ...

Over the last 10 years, breakthroughs in understanding the genetic instructions passed from parent to offspring have put researchers closer than ever before to efficiently decoding DNA with 100% ...